Overview

Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cairo University
Treatments:
Cortisol succinate
Cyclophosphamide
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydroxychloroquine